Managed by Merck & Co., Inc. • Latest filing Q4 2025
Overlap peers will appear here as data populates
Related fund suggestions coming soon.
| $81.2M |
| 14.04M |
| 0.00% |
| — |
| 6 | M MRNA — | $68.1M | 2.31M | 0.00% | — |
| 7 | M MRNA — | $65.4M | 2.31M | 0.00% | — |
| 8 | M MRNA — | $63.7M | 2.31M | 0.00% | — |
| 9 | L LZB — | $60.1M | 772.2K | 0.00% | — |
| 10 | M MRNA — | $59.6M | 2.31M | 0.00% | — |
| 11 | P PR — | $49.3M | 14.04M | 0.00% | — |
| 12 | L LZB — | $43.7M | 772.2K | 0.00% | — |
| 13 | L LZB — | $33.7M | 772.2K | 0.00% | — |
| 14 | L LZB — | $31.1M | 772.2K | 0.00% | — |
| 15 | ? N/A — | $30.1M | 1.74M | 0.00% | — |
| 16 | L LZB — | $21.1M | 772.2K | 0.00% | — |
| 17 | ? N/A — | $17.9M | 1.74M | 0.00% | — |
| 18 | ? N/A — | $15.7M | 1.74M | 0.00% | — |
| 19 | ? N/A — | $11.7M | 1.74M | 0.00% | — |
| 20 | A ALEC — | $10.5M | 3.55M | 0.00% | — |